title: Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis.
abstract: OBJECTIVE
  To compare the cost-effectiveness of different disease-modifying therapies' strategies for treatment of relapsing-remitting multiple sclerosis.
  
  
  METHODS
  A Markov model was developed to assess the cost-effectiveness and incremental cost-effectiveness ratios for different strategies of using disease-modifying therapies from a US third-party payer perspective. All costs were converted to 2014 US$.
  
  
  RESULTS
  Over 20 years, the total costs per patient were estimated at US$161,136.60 for Strategy 1 (symptom management [SM] alone), US$551,650.66 for Strategy 2 (SM and IFN-β-1a), US$703,463.60 for Strategy 3 (SM and natalizumab) and US$670,985.24 for Strategy 4 (SM and alemtuzumab). The accumulated quality-adjusted life years were 10.49, 10.66, 10.69 and 10.71 for each of the four Strategies 1-4, respectively. The resulting incremental cost-effectiveness ratios were 2,297,141.53 comparing Strategy 2 to Strategy 1, and -1,623,918.00 comparing Strategy 4 to Strategy 3.
  
  
  CONCLUSIONS
  Strategy 1 was the cost-effective strategy for treatment of relapsing-remitting multiple sclerosis when compared with other strategies.
authors.affiliation: International Center for Pharmaceutical Economics & Policy, MCPHS University, Boston, MA, USA.|Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
authors.forename: Aseel Bin
authors.initials: AB
authors.lastname: Sawad
authors.affiliation: International Center for Pharmaceutical Economics & Policy, MCPHS University, Boston, MA, USA.
authors.forename: Enrique
authors.initials: E
authors.lastname: Seoane-Vazquez
authors.affiliation: Health Policy & Management Program, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, MA, USA.
authors.forename: Rosa
authors.initials: R
authors.lastname: Rodriguez-Monguio
authors.affiliation: International Center for Pharmaceutical Economics & Policy, MCPHS University, Boston, MA, USA.|Department of Clinical Pharmacy, College of Pharmacy, Taibah University, Medina, Kingdom of Saudi Arabia.
authors.forename: Fatema
authors.initials: F
authors.lastname: Turkistani
mesh_terms: D000074323:Alemtuzumab / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D057915:Drug Substitution; D017048:Health Care Costs; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000191:economics*; D007262:Infusions, Intravenous; D000068556:Interferon beta-1a / Q000008:administration & dosage / Q000191:economics*; D008390:Markov Chains; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000191:economics*; D000069442:Natalizumab / Q000008:administration & dosage / Q000191:economics*; D017063:Outcome Assessment, Health Care; D019057:Quality-Adjusted Life Years
chemical_list: D007155:Immunologic Factors; D000069442:Natalizumab; D000074323:Alemtuzumab; D000068556:Interferon beta-1a
keywords: TreeAge; cost–effectiveness; economic; evaluation; multiple sclerosis; pharmacoeconomic; relapsing-remitting multiple sclerosis